-
CareDx partners with 10x Genomics on transplant rejection research program
-
Craig-Hallum Downgrades CareDx, Inc (CDNA) to Hold 'To Reflect Caution Around Q4 Volume And Uncertainty Around Final LCD Outcome'
-
CareDx study shows HeartCare tests predict heart transplant risks
-
CareDx (CDNA) Tops Q3 EPS by 36c, Beats on Revenue; Offers FY25 Revenue Guidance
-
CareDx launches new transplant diagnostics products and gains EU certification
-
BTIG Reiterates Buy Rating on CareDx, Inc (CDNA)
-
BTIG Reiterates Buy Rating on CareDx, Inc (CDNA)
-
CareDx submits comment on Medicare coverage policy for transplant testing
-
William Blair Starts CareDx, Inc (CDNA) at Market Perform
-
CareDx, Inc (CDNA) PT Lowered to $22 at BTIG
-
CareDx (CDNA) Tops Q2 EPS by 20c
-
CareDx study shows blood test improves kidney transplant monitoring
-
CareDx launches AI-powered transplant diagnostic platform AlloSure Plus
-
CareDx announces draft coverage policy for transplant rejection testing
-
CareDx (CDNA) Announces Repurchase of 5% of Outstanding Shares
-
CareDx, Inc (CDNA) PT Lowered to $30 at BTIG
-
CareDx (CDNA) Tops Q1 EPS by 28c ; Offers Guidance
-
CareDx, Inc (CDNA) PT Lowered to $25 at H.C. Wainwright
-
CareDx (CDNA) Tops Q4 EPS by 41c, provides guidance
-
CareDx (CDNA) Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96M Verdict
-
CareDx (CDNA) Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients
-
CareDx (CDNA) Announces Preliminary Fourth Quarter and Full Year 2024 Results
-
CareDx (CDNA) Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
-
CareDx, Inc (CDNA) PT Lowered to $35 at BTIG
-
CareDx (CDNA) Tops Q3 EPS by 39c, Beats on Revenue; Offers FY24 Revenue Guidance
-
CareDx (CDNA) and Dovetail Genomics Announce Strategic Partnership to Drive Next Wave of Innovation in Transplant Matching with Cutting-Edge Hi-C Technology
-
H.C. Wainwright Reiterates Neutral Rating on CareDx, Inc (CDNA)
-
CareDx (CDNA) Appoints Jing Huang Chief Data and AI Officer
-
BTIG Reiterates Buy Rating on CareDx, Inc (CDNA)
-
CareDx (CDNA) Announces Closure of DOJ Investigation with No Finding of Wrongdoing
-
CareDx (CDNA) Appoints Keith Kennedy as COO, Jessica Meng as CCO
-
BTIG Upgrades CareDx, Inc (CDNA) to Buy
-
CareDx (CDNA) Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap Testing
-
CareDx (CDNA) on watch on positive chatter
-
CareDx, Inc (CDNA) PT Raised to $30 at Jefferies
-
CareDx (CDNA) Tops Q2 EPS by 65c ; Offers Guidance

